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Abstract 
Background: Although the high burden of both active smoking and human immunodeficiency virus (HIV) is clearly 
known, the relationship between them is still not well characterized. Therefore, we estimated the global prevalence 
of active smoking in people living with HIV (PLHIV) on antiretroviral therapy (ART) and investigated the association 
between exposure to active smoking and risk for suboptimal adherence to ART.
Main text: We searched PubMed, Embase, and Web of Science to identify articles published until September 19, 2019. 
Eligible studies reported the prevalence of active smoking in PLHIV on ART or investigated the association between 
active smoking and ART adherence; or enough data to compute these estimates. We used a random-effects model 
to pool data and quantified heterogeneity (I2). The global prevalence of active smoking was 36.1% (95% CI: 33.7–37.2; 
329 prevalence data; 462 104 participants) with substantial heterogeneity. The prevalence increased with level of 
country income; from 10.1% (95% CI: 6.8–14.1) in low-income to 45.2% (95% CI: 42.7–47.7) in high-income countries; 
P < 0.0001. With regards to the Joint United Nations Programme on HIV/AIDS (UNAIDS) regions, the prevalence was 
higher in West and Central Europe and North America 45.4% (42.7–48.1) and lowest in the two UNAIDS regions of 
sub-Saharan Africa: Eastern and Southern Africa 10.7% (95% CI: 7.8–14.0) and West and Central Africa 4.4% (2.9–6.3); 
P < 0.0001. Globally, we estimated that there were 4 110 669 PLHIV on ART who were active smokers, among which 
the highest number was from Eastern and Southern Africa (35.9%) followed by Asia and the Pacific (25.9%). Active 
smoking was significantly associated with suboptimal ART adherence: pooled odds ratio 1.57 (95% CI: 1.37–1.80; 
I2 = 56.8%; 19 studies; 48 450 participants); even after considering adjusted estimates: 1.67 (95% CI: 1.39–2.01; 
I2 = 53.0%; 14 studies).
Conclusions: This study suggests a high prevalence of active smoking in PLHIV on ART and an association between 
active smoking and ART suboptimal adherence. As such, healthcare providers and policy makers should focus on 
adopting and implementing tobacco harm reduction strategies in HIV care, especially in sub-Saharan Africa known as 
epicenter of HIV pandemic with highest number of active tobacco smoking among PLHIV on ART.
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Background
Human immunodeficiency virus (HIV) infection remains 
a global public concern. Globally, there were 37.9 mil-
lion of people living with HIV (PLHIV) by the end of 
2018 [1]. In this population, 24.5 million were accessing 
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antiretroviral therapy (ART) [1, 2]. To curb the burden of 
HIV infection, the Joint United Program on HIV/AIDS 
(UNAIDS) set an ambitious goal that by 2030, 95% of 
all PLHIV should know their HIV status; 95% of people 
diagnosed with HIV infection should receive sustained 
ART; and 95% of all people receiving ART should have 
ribonucleic acid HIV suppression [3]. Since non-adher-
ence to ART is correlated with poor virological response 
to HIV treatment [4], PLHIV should be voluntary com-
pliant to the prescribed ART to achieve the third 95.
Active tobacco smoking could be one of the fac-
tors which would prevent reaching the goal. However, 
to date, it is not clear whether active smoking could 
be associated with suboptimal adherence to ART in 
PLHIV. Globally, tobacco smoking is one of the biggest 
public health threats the world has ever faced, killing 
more than 8 million people annually [5]. In addition, 
tobacco is one of the leading risk factors for cardiovas-
cular diseases, the top killer worldwide [6]. In 2018, 770 
000 people died from AIDS-related illnesses [1, 2]. In 
addition, HIV infection is now recognized as risk fac-
tor of cardiovascular diseases (the top killer worldwide) 
alongside with traditional cardiovascular risk factors 
[6].
Although the high burden of both active smoking 
and HIV is clearly known, the relationship between 
them and the burden of active smoking in PLHIV on 
ART are still not well characterized. Accurate global 
and context-specific epidemiological data are cru-
cial to tackle the burden of active smoking in PLHIV, 
especially for health-care planning and resource alloca-
tions. Hence, we conducted this systematic review with 
meta-analysis to determine the burden of active smok-
ing in PLHIV undergoing ART. Firstly, we estimated the 
global prevalence of active smoking in PLHIV on ART 
and estimated this prevalence by UNAIDS region and 
country level of income. Secondly, we provided the bur-
den of active smoking in terms of number of smokers in 
PLHIV on ART at global and UNAIDS regional levels. 
Finally, we investigated the association between expo-
sure to active smoking and risk for suboptimal adher-
ence to ART in PLHIV.
Methods
Eligibility criteria
We used the same method as per already published meta-
analyses [7, 8]. This systematic review and meta-analysis 
was conducted according to the Joanna Briggs Institute 
guidelines [9]. This study was reported according to the 
PRISMA guidelines [10]. The protocol of this review was 
registered in PROSPERO, CRD42020195796.
We considered observational studies including 
cross sectional, case-control, and cohort studies. We 
considered studies reporting the prevalence (or enough 
data to compute this estimate) of current or active 
tobacco smoking (willful or deliberate act of inhaling and 
exhaling smoke from burning substances or agents held 
by hand) in the global population of PLHIV undergo-
ing ART (at least 90% of PLHIV with ART) [11]. We also 
considered studies investigating the association between 
active tobacco smoking and ART suboptimal adherence 
in PLHIV.
Search strategy
We searched PubMed, Excerpta Medica Database 
(EMBASE), and Web of Science to identify all relevant 
records published up to September  19th, 2019 without 
any language restriction. The search strategy in EMBASE 
is available in the Appendix (Supplementary Table  1). 
This search was adapted to suit with other databases. 
To supplement the bibliographic database searches and 
identify potential additional data sources, we scrutinized 
the reference list of all relevant review papers.
Study selection
Titles and abstracts of articles retrieved from literature 
search were independently screened by two investiga-
tors, and the full-texts of those potentially eligible were 
obtained and further assessed for final inclusion. Disa-
greements were resolved through consensus.
Data extraction and management
A preconceived and standardized data extraction form 
was used to collect information on first author’s name, 
study country, year of publication, period of participants’ 
recruitment, study design, setting, sampling method, 
timing of data collection, response rate, mean or median 
age of the population, proportion of males, proportion 
with antiretroviral treatment, number of PLHIV, the 
number of participants with active smoking. For stud-
ies investigating the association between active tobacco 
smoking and adherence to antiretroviral therapy, we also 
extracted data for participants with no active smoking, 
data on the adherence as defined in the original studies, 
and variables of adjustment in multivariable analysis. 
Studies were classified by level of income according to 
the country of recruitment of participants as per World 
Bank classification [12]. Ten investigators independently 
extracted data from individual studies, with disagree-
ments being resolved through discussion. Ten investiga-
tors independently assessed methodological quality of 
included studies with tool developed by Joanna Briggs 
Institute for prevalence data and with Newcastle Ottawa 
Scale for comparative studies investigating the associa-
tion between active tobacco smoking and ART adherence 
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[9, 13]; with disagreements being resolved through 
discussion.
Data synthesis and analysis
Meta-analyses were performed with the meta, metafor, 
and dmetar packages of the statistical software R (version 
3.6.3, R foundation for Statistical Computing, Vienna, 
Austria). Prevalence estimates were reported with 95% 
confidence interval (95% CI). Prevalence pooling was 
done with single arcsine transformation using random-
effects meta-analysis model [14]. Sensitivity analyses was 
performed including only studies with low risk of bias for 
each of defined items. We estimated an adjusted global 
prevalence taking in account the variability between 
UNAIDS region and country level of income. Publica-
tion bias was investigated with funnel plot and confirmed 
with the Egger’s test [15]. A P-value < 0.10 on the Egger 
test was considered indicative of statistically significant 
publication bias. We performed meta-regression analysis 
and estimated the variance explained by study and par-
ticipants’ characteristics. In this analysis, the outcome of 
interest was the prevalence of active smoking in patients 
undergoing ART, included as a continuous variable. The 
final multivariable model was chosen based on the low-
est corrected Akaike’s Information Criterion. For miss-
ing data, we have performed a non-parametric test of 
homoscedasticity and there was not sufficient evidence 
to reject that data were missing completely at random, 
P = 0.450. Therefore, we have performed multiple-impu-
tation analyses using chained equations for studies who 
had a missing value. We generated 40 imputed-data sets 
with a maximum number of 10 iterations, with linear 
imputation for continuous variables [16]. Variables that 
were included in the imputation model were proportion 
of males, mean age, duration of since HIV diagnosis and 
duration on ART. We have also performed a meta-regres-
sion analysis with complete cases.
To measure the association between active tobacco 
smoking and non-adherence to ART, we did a meta-anal-
ysis using the random-effects method to pool weighted 
(adjusted) odds ratios (OR) of suboptimal ART adherence 
risk estimate. The symmetry of funnel plot was used to 
explore publication bias and Harbord test was done to 
assess the presence of publication bias [17].
Heterogeneity was evaluated by the χ2 test on Cochran’s 
Q statistic [18], which was quantified by I2 values. The I2 
statistic estimates the percentage of total variation across 
studies due to true difference between-study differences 
rather than chance. In general, I2 values greater than 




Of the 2329 records identified, we included 290 studies 
with 329 prevalence data for estimating the prevalence 
Table 1 Meta-analysis prevalence of active smoking in people living with HIV undergoing antiretroviral therapy
HIV Human immunodeficiency virus, ART antiretroviral therapy, UNAIDS Joint United Program on HIV, NA not applicable
Prevalence, % 95% 
confidence 
intervals
No. studies No. participants Heterogeneity Egger test P value, difference
I2, % P value
Global 36.1 33.7–38.5 329 462 104 99.5  < 0.0001 0.0002 …
 All participants on ART 34.5 31.8–37.2 268 420 575 99.6  < 0.0001 0.0001 …
Country level of income
 Low 10.1 6.8–14.1 30 11 329 95.9  < 0.0001 0.095  < 0.0001
 Lower-middle 16.0 8.6–25.3 21 9858 98.7  < 0.0001 0.496
 Upper-middle 27.6 23.8–31.6 39 8252 90.4  < 0.0001 0.668
 High 45.2 42.7–47.7 216 339 022 99.5  < 0.0001 0.527
UNAIDS region
 West and Central Africa 4.4 2.9–6.3 12 4868 87.0  < 0.0001 0.263  < 0.0001
 Eastern and Southern Africa 10.7 7.8–14.0 34 12 676 94.8  < 0.0001 0.080
 Latin America and the 
Caribbean
28.8 25.0–32.8 24 16 385 95.9  < 0.0001 0.162
 Asia and Pacific 32.6 26.6–38.9 27 16 352 97.3  < 0.0001 0.031
 Middle East and North Africa 32.9 16.1–52.4 3 320 93.0  < 0.0001 0.711
 Eastern Europe and Central 
Asia
43.1 15.8–72.9 2 264 95.9  < 0.0001 NA
 West and Central Europe 
and North America
45.4 42.7–48.1 203 293 547 99.5  < 0.0001 0.339
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of active smoking in PLHIV on ART and 19 studies for 
investigating the association between active tobacco 
smoking and ART adherence (Additional file 1: Figure S1).
Of the 290 studies included in the meta-analysis of 
prevalence, most of them were cross-sectional, hospital-
based, and published between 2000 and 2019 (Additional 
file 1: Tables S2 and S3). According to the methodological 
quality, most of studies used non-probabilistic sampling, 
had low precision, had unclear description of response 
rate, were prospectively collected data, and used identical 
procedure to collect data among participants (Additional 
file 1: Tables S2 and S3).
Of the 19 studies included in the meta-analysis for the 
association between active tobacco smoking and adher-
ence to ART, most of them were cross-sectional and 
hospital-based, had low risk of bias on the selection of 
participants, included comparable groups and outcome 
assessment, and were published between 2006 and 2019 
(Additional file  1: Tables S4 and S5). All studies used 
non-probabilistic sampling.
Prevalence of active tobacco smoking in the global 
population living with HIV
Of the 329 prevalence data, 216 (65.7%) were from 
high, 39 (11.9%) from upper-middle, 21 (6.4%) from 
lower-middle, and 30 (9.1%) from low-income countries. 
Twenty-three (7.0%) were not disagreeable. Accord-
ing to the UNAIDS regional distribution, 203 (61.7%) 
prevalence data were from West and Central Europe and 
North America, 34 (10.3%) from Eastern and Southern 
Africa, 27 (8.2%) form the Asia and Pacific, 24 (7.3%) 
from Latin America and the Caribbean, 12 (3.7%) from 
West and Central Africa, 3 (0.9%) from Middle-East and 
North Africa, and 2 (0.6%) from Eastern Europe and 
Central Asia. Twenty-four (7.3%) prevalence data were 
multiregional. According to participants’ characteris-
tics, the mean or median age varied from 16.7 to 66 years 
(n = 290), the proportion of males varied from 0 to 100% 
(n = 301), the duration since HIV diagnosis varied from 
0.5 to 22 years (n = 119), and the duration on ART varied 
from 0.7 to 18.4 years (n = 98).
The global prevalence of active smoking in a total of 462 
104 PLHIV undergoing ART was 36.1% (95% CI: 33.7–
37.2) with substantial heterogeneity (Table 1). There was 
asymmetry on the funnel plot corroborated by the Egger 
test (Additional file  1: Figure S2; Table  1). The preva-
lence from sensitivity analyses including studies with all 
patients undergoing ART, and only studies with low risk 
of bias were close to crude prevalence (Additional file 1: 
Tables S6). Although in the range of the global crude 
Fig. 1 Meta-analysis prevalence of active smoking in people living with HIV on antiretroviral therapy by country level of income
Page 5 of 12Ale et al. Infect Dis Poverty           (2021) 10:12  
prevalence, the adjusted prevalence taking in account the 
variance between country level of income and UNAIDS 
regions was slightly lower: 27.3% (16.9–39.2).
Sources of heterogeneity of the global prevalence
In subgroup analysis, the prevalence increased with level 
of country income; from 10.1% (6.8–14.1) in low-income 
countries to 45.2% (42.7–47.7) in high-income countries, 
P < 0.0001 (Fig. 1). According to the UNAIDS region, the 
lowest prevalence was in sub-Saharan Africa regions: 
West and Central Africa 4.4% (2.9–6.9) and Eastern and 
Southern Africa 10.7% (7.8–14.0) and the highest preva-
lence was in West and Central Europe and North Amer-
ica 45.4% (42.7–48.1), P < 0.0001 (Fig. 2; Additional file 1: 
Figures S3 to S9). Males were more likely to smoke than 
females: pooled OR = 2.41 (95% CI: 1.27–4.60; I2 = 96.3%; 
20 studies) (Fig. 3).
In the univariable meta-regression analysis, the 
explained variance in the global prevalence varied from 
0.1% for response rate to 45.3% for UNAIDS region 
(Table  2). The variation in the global prevalence signifi-
cantly increased with country level of income, proportion 
of males, duration since HIV infection diagnosis, duration 
on ART, increasing age, and was associated with UNAIDS 
region (Table 2). There was no difference with the analysis 
considering complete cases (Additional file 1: Tables S7).
In the final multivariable meta-regression model, 
the global prevalence increased with country level of 
Fig. 2 Meta-analysis prevalence of active smoking in people living with HIV on antiretroviral therapy by UNAIDS region
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income. The prevalence was lower in Eastern and South-
ern Africa, in West and Central Africa, in Latin America 
and the Caribbean compared to West and Central Europe 
and North America. There was no difference for other 
regions. These two variables accounted for 47.3% of the 
variation in the global prevalence (Table  2). The same 
variables were included in the final model considering 
completes cases (Additional file 1: Tables S7).
Burden of active tobacco smoking in people undergoing 
antiretroviral treatment
Considering regional estimates, 35.9% of PLHIV under-
going ART were from Eastern and Southern Africa, fol-
lowed by Asia and Pacific (25.4%) and West and Central 
Europe and North America (18.8%). Globally, 4 110 669 
PLHIV undergoing ART were active smokers (Table 3).
Active tobacco smoking and adherence to antiretroviral 
therapy
We included 19 studies with 48 450 PLHIV undergoing 
ART in the meta-analysis for investigating the associa-
tion between active tobacco smoking and suboptimal 
adherence to ART. There was clinical heterogeneity 
in the definition of adherence to ART across included 
studies (Additional file  1: Tables S5). The risk for sub-
optimal adherence to ART was significantly higher in 
patients with active tobacco smoking than in non-active 
smoking: pooled OR = 1.57 (95% CI: 1.37–1.80; I2: 
56.8%; 19 studies) (Fig. 4a). There was no asymmetry on 
the funnel plot (Additional file  1: Fig. S10), confirmed 
by the Harbord test (P = 0.293). The meta-analysis of 
adjusted OR yielded a pooled estimate of 1.67 (95% CI: 
1.39–2.01; I2 = 53.0%; 14 studies) (Fig.  4b). There was 
no asymmetry on the funnel plot (Additional file 1: Fig. 
S11), confirmed by the Harbord test (P = 0.410).
Discussion
In this meta-analysis of 329 prevalence data with 462 104 
PLHIV on ART, we found that more than third of them 
actively smoke tobacco. The prevalence of active tobacco 
smoking in PLHIV in ART was higher in Western & Cen-
tral Europe and North America UNAIDS region. How-
ever, the burden in terms of number of PLHIV on ART 
that actively smoke was higher in Eastern and South-
ern Africa. The prevalence increased with country level 
of income and was higher among males compared to 
females. We also found that active smoking was associ-
ated with suboptimal ART adherence.
The prevalence of active smoking in PLHIV on ART 
found in this study is close to the one reported among 
females in a previous meta-analysis of 51 studies (36.3%, 
95% CI: 28.0–45.4%) and slightly lower compared to the 
one reported among males (50.3%, 95% CI: 44.4–56.2% 
Fig. 3 Association between male sex and active smoking in people living with HIV on antiretroviral therapy
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in the same study [20]. Another meta-analysis of 31 stud-
ies found a prevalence 46.5% (95% CI: 40.9–52.1) among 
PLHIV regardless of their ART status [21]. Our review 
included more studies and focused on PLHIV undergo-
ing ART. In addition, our review also represents a more 
contemporary and global estimate. Like in the general 
population [22, 23], the odds ratio of active smoking was 
higher among males compared to females in this study. In 
the global general population, about 40% of men smoke 
as compared to nearly 9% of women [22]. Indeed, results 
from neuroimaging studies suggest that smoking acti-
vates men’s reward pathways more than women [24]. This 
is reflected by higher odds of smoking among men com-
pared to women in this meta-analysis and other meta-
analyses of PLHIV regardless of their ART status [20, 21].
The prevalence increased with country level of income. 
We found a higher prevalence in the Western and Central 
Europe and North America UNAIDS region (where most 
of the countries are classified as high-income) and lower 
in all UNAIDS Africa regions (West and Central Africa 
and Eastern and Southern Africa, where most of the 
countries are classified as low and lower-middle income). 
This might be explained by the fact that tobacco is more 
affordable for populations with higher socioeconomic 
status. In addition, people have less chance to smoke in 
warm-weather context where most of low- and lower-
middle income countries are located [25]. Furthermore, 
Western & Central Europe and North America coun-
tries might be culturally more prone to smoke. Indeed, 
in the general population, age-standardized prevalence of 
tobacco smoking among persons 15 years and older was 
higher in World Health Organization (WHO) Europe 
region in 2016 and may partly explain a higher preva-
lence of active smoking in PLHIV on ART in Western 
and Central Europe and North America UNAIDS coun-
tries [26]. Although, Western and Central Europe and 
North America UNAIDS region had the highest preva-
lence of active smoking, the burden in terms of num-
ber of active smokers in PLHIV on ART was higher in 
Eastern and Southern Africa, which accounted for almost 
one-third of all PLHIV with active smoking. Hence, pri-
oritization of resources and implementation of context-
specific public health interventions to curb the burden of 
active smoking in PLHIV should be designed to address 
sub-Saharan Africa in particular.
We found that the odd of suboptimal ART adherence 
was significantly higher in active smokers compared to 
non-active. Evidence indicate that structural and socio-
economic conditions, as well as psychosocial factors 
(depression, anxiety), that were associated with smoking 
behavior are also predictive of suboptimal ART adher-
ence. Prior research indicates that smokers, compared 
with nonsmokers tended to have multiple and inter-
related structural and socioeconomic conditions, as well 
as psychosocial factors, that were associated with sub-
optimal ART adherence [27]. Improved understanding 
of the ways in which these factors co-occur and affect 
health-related behaviors may improve the efforts to 
decrease the burden of tobacco smoking when integrat-
ing adherence interventions into clinical settings.
Our findings have important policy implications for 
the management of PLHIV on ART because among the 
24.5 million PLHIV ongoing ART worldwide [1], more 
than 4 million are active smokers and may not achieve 
HIV viral suppression due to suboptimal ART adher-
ence. Both HIV-itself and tobacco smoking are associ-
ated with numerous health concerns including but not 
limited to cancer, cardiovascular diseases, hypertension, 
lung diseases, diabetes, tuberculosis, immune system 
diseases, and chronic obstructive pulmonary disease [7, 
28–31]. Therefore, curbing the burden of tobacco smok-
ing in PLHIV on ART is paramount and requires efficient 
interventions against this modifiable behavior and risk 
factor since ART initiation do not favor quitting smok-
ing [32]. The high active smoking prevalence found in 
this study calls all HIV healthcare providers to pay more 
attention to this dreadful public health concern and to 
integrate quitting tobacco interventions in already built 
Table 3 Global and regional estimates of active smoking in people living with HIV undergoing antiretroviral therapy
HIV Human Immunodeficiency Virus, PLHIV People living with HIV, ART Antiretroviral treatment




Global 4 110 669 …
Eastern and Southern Africa 1 476 600 35.9%
Asia and the Pacific 1 043 200 25.4%
West and Central Europe and North America 771 800 18.8%
Latin America and the Caribbean 399 456 9.7%
Eastern Europe and Central Asia 279 288 6.8%
West and Central Africa 114 400 2.8%
Middle East and North Africa 25 925 0.6%
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HIV services. All PLHIV with active smoking should be 
identified and solutions to quit smoking should be imple-
mented including but not limited to mobile phone-based, 
internet-based, pharmacotherapy-based, nicotine-based, 
incentives, counseling, and motivational interview inter-
ventions [33–44]. Future research should investigate 
quitting tobacco smoking in the specific population of 
PLHIV on ART. Countries should fully implement the 
six MPOWER guidelines issued by the WHO. To date, 
only Brazil and Turkey have had the highest level of 
achievement in terms of this guidelines implementation 
[5].
The findings of this review should be interpreted con-
sidering some limitations. First, we included some stud-
ies with moderate to high risk of bias. However, when 
pooling only studies having a low risk of bias, the overall 
estimate was close to that of the crude analysis. Second, 
we found a huge statistical heterogeneity between stud-
ies for which we undertook subgroup and meta-regres-
sion analyses to identify sources of heterogeneity. This is 
Fig. 4 Association between active smoking and suboptimal adherence to antiretroviral therapy in people living with HIV. a Crude estimate, b 
Adjusted estimate
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most common to meta-analyses of prevalence data [45]. 
However, some characteristics that may further explain 
heterogeneity were not consistently reported in the origi-
nal studies such as HIV clinical stage, immunological sta-
tus, HIV viral load and detailed ART regimen to further 
explore other sources of heterogeneity. Third, the various 
geographic regions and countries were variably repre-
sented. This may weaken the generalizability of our find-
ings. To take in account this variability, we performed a 
hierarchical meta-analysis considering the variance from 
UNAIDS regions and country level of income. Fourth, 
there was methodological and clinical heterogeneity 
on the method to measure ART adherence, and ART 
regimen information was lacked or was not consistently 
reported across included studies. Therefore, we were not 
able to statistically quantify this heterogeneity although 
this was not substantial when measuring the association 
between active smoking and ART adherence. Finally, 
there were some missing data concerning study charac-
teristics for which we have undertaken multiple imputa-
tion to address this limitation. Despite these limitations, 
this systematic review and meta-analysis provided a clear 
summary of the existing knowledge on the global bur-
den of active smoking among PLHIV on ART at global 
and regional levels and according to the country level 
of income. It is also the first measuring the association 
between active smoking and ART adherence.
Conclusions
This study suggests a high prevalence of active smoking 
in PLHIV on ART and an association between active 
smoking and ART suboptimal adherence. As such, 
active smoking in PLHIV should be prioritized among 
HIV health care providers, policy makers and stake-
holders from the health sector for improved detec-
tion, overall proper management and efficient control. 
This study supports the need for specific strategies to 
reduce the burden of active smoking in PLHIV, with 
primer focus on males and on sub-Saharan Africa, the 
epicenter of HIV pandemic with the highest number of 
active smokers among PLHIV on ART.
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